Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1141 ARTÍCULOS , VIENDO DEL 106 AL 120

Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study

Gauthier S, Robillard A, Cohen S, Black S, Sampalis J, Colizza D, de Takacsy F, Schecter R; EMBRACE investigators.

Curr Med Res Opin. 2013 Aug;29(8):989-1000. doi: 10.1185/03007995.2013.802230. Epub 2013 May 23.

Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease

Parsons CG, Danysz W, Dekundy A, Pulte I.

Neurotox Res. 2013 Oct;24(3):358-69. doi: 10.1007/s12640-013-9398-z. Epub 2013 May 9.

Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits

Davie BJ, Christopoulos A, Scammells PJ.

ACS Chem Neurosci. 2013 Jul 17;4(7):1026-48. doi: 10.1021/cn400086m. Epub 2013 May 23.

β-Arrestins as potential therapeutic targets for Alzheimer's disease

Jiang T, Yu JT, Tan MS, Zhu XC, Tan L.

Mol Neurobiol. 2013 Dec;48(3):812-8. doi: 10.1007/s12035-013-8469-8. Epub 2013 May 16.

[Nicotinic acetylcholine receptor in Alzheimer's disease]

Abe K.

Nihon Rinsho. 2013 Apr;71(4):743-50.

Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story

Stamford A, Strickland C.

Curr Opin Chem Biol. 2013 Jun;17(3):320-8. doi: 10.1016/j.cbpa.2013.04.016. Epub 2013 May 14.

Immunotherapy in Alzheimer's disease: do we have all the pieces of the puzzle?

Sarazin M, Dorothée G, de Souza LC, Aucouturier P.

Biol Psychiatry. 2013 Sep 1;74(5):329-32. doi: 10.1016/j.biopsych.2013.04.011. Epub 2013 May 14.

The amyloid precursor protein: a biochemical enigma in brain development, function and disease

Nalivaeva NN, Turner AJ.

FEBS Lett. 2013 Jun 27;587(13):2046-54. doi: 10.1016/j.febslet.2013.05.010. Epub 2013 May 16.

Atrial flutter in a patient with Alzheimer dementia treated by rivastigmine

Hsu YC, Chao CY, Chang HA, Hwang SY, Tzeng NS.

J Neuropsychiatry Clin Neurosci. 2013 Spring;25(2):E25-6. doi: 10.1176/appi.neuropsych.12030063.

The NLRP3 inflammasome in Alzheimer's disease

Tan MS, Yu JT, Jiang T, Zhu XC, Tan L.

Mol Neurobiol. 2013 Dec;48(3):875-82. doi: 10.1007/s12035-013-8475-x. Epub 2013 May 19.

An open-label, nonplacebo-controlled study on Cistanche tubulosa glycoside capsules (Memoregain(®)) for treating moderate Alzheimer's Disease

Guo Q, Zhou Y, Wang CJ, Huang YM, Lee YT, Su MH, Lu J.

Am J Alzheimers Dis Other Demen. 2013 Jun;28(4):363-70. doi: 10.1177/1533317513488907. Epub 2013 May 17.

Prediction models for assessing long-term outcome in Alzheimer's disease: a review

Wattmo C.

Am J Alzheimers Dis Other Demen. 2013 Aug;28(5):440-9. doi: 10.1177/1533317513488916. Epub 2013 May 20.

[Effectiveness and limitation of newly approved drugs for Alzheimer's disease]

Hattori H.

Seishin Shinkeigaku Zasshi. 2013;115(1):22-31.

DNA Aβ42 vaccination as possible alternative immunotherapy for Alzheimer disease

Rosenberg RN, Lambracht-Washington D.

JAMA Neurol. 2013 Jun;70(6):772-3. doi: 10.1001/jamaneurol.2013.1502.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias